Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Infliximab Kit ELISA

Reactivité: Humain, Souris, Rat Colorimetric Sandwich ELISA 0.78-25 ng/mL Plasma, Serum
N° du produit ABIN4886393
  • Antigène Tous les produits Infliximab
    Infliximab
    Reactivité
    • 1
    • 1
    • 1
    • 1
    Humain, Souris, Rat
    Méthode de détection
    Colorimetric
    Type de méthode
    Sandwich ELISA
    Gamme de detection
    0.78-25 ng/mL
    Seuil minimal de détection
    0.78 ng/mL
    Application
    ELISA
    Fonction
    Quantification of Infliximab in biological matrices
    Type d'échantillon
    Plasma, Serum
    Analytical Method
    Quantitative
    Specificité
    Infliximab (Remicade)
    Réactivité croisée (Details)
    hIgG1 and Infliximab prepared at 250 ng/ mL were assayed and exhibited no cross-reactivity or interference.
    Ingrédients
    Coated microtiter plate, 96 wells
    Calibrator diluent. - 1.8ml
    Calibrator 12ul
    10X wash buffer - 25ml
    Assay buffer - 50ml
    1000X detection reagent - 17ul
    TMB - 12ml
    TMB stop solution - 12ml
    Plate sealers - 3
    Matériel non inclus
    Precision pipettes calibrated to deliver 5-1000μL
    Multi-channel pipette calibrated to deliver 50-200μL
    Plate shaker
    Disposable tips
    Vortex-Mixer
    Distilled or de-ionized water
    Microplate reader capable of reading 450nm with background subtrac
  • Indications d'application
    Optimal working dilution should be determined by the investigator.
    Volume d'échantillon
    15 μL
    Durée du test
    2.5 h
    Plaque
    Pre-coated
    Protocole
    The Infliximab ELISA kit is designed to measure free Infliximab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Infliximab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples and the concentration is calculated from the standard series.
    Préparation des réactifs

    Prepare the appropriate amount of required reagent on the day of use. Store all reagents as per instructions stated on the label. 1. Wash Buffer (1X) Preparation: Dilute wash buffer concentrate with ultra-pure water 1/10 before use (for example add 20 mL concentrate to 180 mL ultra-pure water). Mix well. 2. Detection Reagent (1X) Preparation: Dilute detection reagent with assay buffer 1/1000 before use (for example add 11 μL concentrate to 11 mL of assay buffer). Mix well. 3. Preparation of Calibrators: Prepare calibrators with concentrations ranging from 2,500 ng/mL to 78 ng/ mL. The following is an example calibrator curve.

    Prélèvement de l'échantillon
    This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20 °C for up to 1 year.
    Préparation de l'échantillon

    Dilute calibrators and test samples 1/100 with assay buffer (for example add 5μL of prepared calibrator or sample to 495μL of assay buffer). Mix well. *Note that test samples may require further dilution when peak values are predicted to exceed 2.5 μg/mL.

    Procédure de l'essai

    This assay employs the sandwich enzyme immunoassay technique. Anti- Infliximab is coated onto a 96 well microplate. Calibrator, quality control samples (if desired) and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized anti- Infliximab antibody. After washing away any unbound substances, enzyme linked anti- Infliximab antibody is added to the wells. This antibody is developed and purified specifically against truncated Remicade® (domain residing in Fc portion of the Remicade® molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples. The color development is stopped and the intensity of the color is measured.

    Calcul des résultats
    1. Construct a standard curve by plotting the absorbance obtained from each standard against concentration. Use a 4 or 5 parameter curve fit. Alternatively a log-log curve fit may be used. 2. The concentration of the unknowns can be read directly from this standard curve using the absorbance value for each sample. 3. Any sample undiluted or diluted still reading greater than the highest standard should be diluted appropriately with calibrator diluent and retested. If the samples have been diluted, the concentration determined from the standard curve must be multiplied by the dilution factor.
    Précision du teste
    Precision: The precision was determined by analyzing samples prepared at 1000 ng/mL in 6 replicates on 6 different occasions. Intra-assay coefficient of variation (CV) < 10%. Inter-assay CV < 10%.

    Recovery: 1000 ng/mL of Infliximab was spiked in 10 lots of human serum. Recovery ranges are from 93-109% with an average recovery of 97%.
    Restrictions
    For Research Use only
  • Agent conservateur
    Without preservative
    Précaution d'utilisation
    Read manual completely before beginning
    Stock
    -20 °C
    Stockage commentaire
    Store kit components at -20°C unless specified otherwise. DO NOT USE past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening.
    Date de péremption
    12 months
  • Antigène Tous les produits Infliximab
    Infliximab
    Abstract
    Infliximab Produits
    Classe de substances
    Antibody
    Sujet
    Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF- α). Infliximab neutralizes the biological activity of TNF- α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors.
    ID gène
    7124
Vous êtes ici:
Support technique